...
ctxr-img

Citius Pharmaceuticals Inc, Common Stock

CTXR

NAQ

$2.66

-$0.07

(-2.56%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$87.15M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
28.16K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.66
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.44 L
$26.75 H
$2.66

About Citius Pharmaceuticals Inc, Common Stock

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameCTXRSectorS&P500
1-Week Return-16.51%-3.39%0.2%
1-Month Return-51.29%-1.92%2.72%
3-Month Return-78.2%-10.54%7.31%
6-Month Return-82.28%-4.47%10.44%
1-Year Return-85.79%4.06%27.53%
3-Year Return-93.04%0.94%30.88%
5-Year Return-81.8%36.67%89.21%
10-Year Return-99.41%102.87%199.95%

Financials

Sep '19Sep '20Sep '21Sep '22Sep '235YR TREND
Total Revenue-----[{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]
Cost of Revenue893.00152.36K164.87K179.68K194.32K[{"date":"2019-09-30","value":0.46,"profit":true},{"date":"2020-09-30","value":78.41,"profit":true},{"date":"2021-09-30","value":84.85,"profit":true},{"date":"2022-09-30","value":92.47,"profit":true},{"date":"2023-09-30","value":100,"profit":true}]
Gross Profit(893.00)(152.36K)(164.87K)(179.68K)(194.32K)[{"date":"2019-09-30","value":-89300,"profit":false},{"date":"2020-09-30","value":-15236400,"profit":false},{"date":"2021-09-30","value":-16486800,"profit":false},{"date":"2022-09-30","value":-17967700,"profit":false},{"date":"2023-09-30","value":-19431600,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-09-30","value":null,"profit":false},{"date":"2020-09-30","value":null,"profit":false},{"date":"2021-09-30","value":null,"profit":false},{"date":"2022-09-30","value":null,"profit":false},{"date":"2023-09-30","value":null,"profit":false}]
Operating Expenses15.60M17.71M23.53M33.32M36.73M[{"date":"2019-09-30","value":42.47,"profit":true},{"date":"2020-09-30","value":48.22,"profit":true},{"date":"2021-09-30","value":64.06,"profit":true},{"date":"2022-09-30","value":90.7,"profit":true},{"date":"2023-09-30","value":100,"profit":true}]
Operating Income(15.60M)(17.71M)(23.53M)(33.32M)(36.73M)[{"date":"2019-09-30","value":-1559836100,"profit":false},{"date":"2020-09-30","value":-1771068500,"profit":false},{"date":"2021-09-30","value":-2353189400,"profit":false},{"date":"2022-09-30","value":-3331604500,"profit":false},{"date":"2023-09-30","value":-3673201800,"profit":false}]
Total Non-Operating Income/Expense72.43K214.99K728.45K502.80K5.94M[{"date":"2019-09-30","value":1.22,"profit":true},{"date":"2020-09-30","value":3.62,"profit":true},{"date":"2021-09-30","value":12.25,"profit":true},{"date":"2022-09-30","value":8.46,"profit":true},{"date":"2023-09-30","value":100,"profit":true}]
Pre-Tax Income(15.56M)(17.55M)(23.05M)(33.06M)(31.97M)[{"date":"2019-09-30","value":-1556214400,"profit":false},{"date":"2020-09-30","value":-1754808500,"profit":false},{"date":"2021-09-30","value":-2305443400,"profit":false},{"date":"2022-09-30","value":-3306464600,"profit":false},{"date":"2023-09-30","value":-3196691200,"profit":false}]
Income Taxes16.44K125.88K70.76K576.00K576.00K[{"date":"2019-09-30","value":2.85,"profit":true},{"date":"2020-09-30","value":21.85,"profit":true},{"date":"2021-09-30","value":12.28,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":100,"profit":true}]
Income After Taxes(15.58M)(17.67M)(23.13M)(33.64M)(32.54M)[{"date":"2019-09-30","value":-1557858700,"profit":false},{"date":"2020-09-30","value":-1767396500,"profit":false},{"date":"2021-09-30","value":-2312519000,"profit":false},{"date":"2022-09-30","value":-3364064600,"profit":false},{"date":"2023-09-30","value":-3254291200,"profit":false}]
Income From Continuous Operations(15.56M)(17.55M)(23.05M)(33.64M)(32.54M)[{"date":"2019-09-30","value":-1556214400,"profit":false},{"date":"2020-09-30","value":-1754808500,"profit":false},{"date":"2021-09-30","value":-2305443400,"profit":false},{"date":"2022-09-30","value":-3364064600,"profit":false},{"date":"2023-09-30","value":-3254291200,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}]
Net Income(15.58M)(17.67M)(23.13M)(33.64M)(32.54M)[{"date":"2019-09-30","value":-1557858700,"profit":false},{"date":"2020-09-30","value":-1767396500,"profit":false},{"date":"2021-09-30","value":-2312519000,"profit":false},{"date":"2022-09-30","value":-3364064600,"profit":false},{"date":"2023-09-30","value":-3254291200,"profit":false}]
EPS (Diluted)(0.78)(0.46)(0.27)(0.22)(0.23)[{"date":"2019-09-30","value":-78,"profit":false},{"date":"2020-09-30","value":-46,"profit":false},{"date":"2021-09-30","value":-27,"profit":false},{"date":"2022-09-30","value":-22,"profit":false},{"date":"2023-09-30","value":-23,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CTXR
Cash Ratio 4.31
Current Ratio 6.75

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CTXR
ROA (LTM) -24.74%
ROE (LTM) -41.49%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CTXR
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CTXR
Trailing PE NM
Forward PE 9.13
P/S (TTM) 0.00
P/B 0.25
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Citius Pharmaceuticals Inc share price today?

Citius Pharmaceuticals Inc (CTXR) share price today is $2.66

Can Indians buy Citius Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Citius Pharmaceuticals Inc (CTXR) on Vested. To buy Citius Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CTXR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Citius Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Citius Pharmaceuticals Inc (CTXR) via the Vested app. You can start investing in Citius Pharmaceuticals Inc (CTXR) with a minimum investment of $1.

How to invest in Citius Pharmaceuticals Inc shares from India?

You can invest in shares of Citius Pharmaceuticals Inc (CTXR) via Vested in three simple steps:

  • Click on Sign Up or Invest in CTXR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Citius Pharmaceuticals Inc shares
What is Citius Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Citius Pharmaceuticals Inc (CTXR) is $26.75. The 52-week low price of Citius Pharmaceuticals Inc (CTXR) is $2.44.

What is Citius Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Citius Pharmaceuticals Inc (CTXR) is

What is Citius Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Citius Pharmaceuticals Inc (CTXR) is 0.25

What is Citius Pharmaceuticals Inc dividend yield?

The dividend yield of Citius Pharmaceuticals Inc (CTXR) is 0.00%

What is the Market Cap of Citius Pharmaceuticals Inc?

The market capitalization of Citius Pharmaceuticals Inc (CTXR) is $87.15M

What is Citius Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Citius Pharmaceuticals Inc is CTXR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top